Jonathan Aschoff's Stock Ratings

Roth Capital Analyst

Jonathan Aschoff is an analyst at Roth Capital. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 12/16/2025

Updated: Dec 16, 2025

Overall Average Return

-35.1%

Smart Score

32.7%

Overall Average Return Percentile

5th

Number of Ratings

3
Buy NowGet Alert
11/25/2025PTHSBuy Now
Pelthos Therapeutics
$22.15157.34% → $57Initiates → BuyGet Alert
07/09/2025OTRKBuy Now
Ontrak
$0.064891.68%$4 → $3MaintainsBuyGet Alert
12/02/2024GTBPBuy Now
GT Biopharma
$0.691491.9% → $11Initiates → BuyGet Alert

Recent Analyst Stock Rating News

Alphabet To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Wednesday
Alphabet To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Wednesday
Beyond The Numbers: 7 Analysts Discuss Zevra Therapeutics Stock
Beyond The Numbers: 7 Analysts Discuss Zevra Therapeutics Stock
Why Bank of Marin Bancorp Shares Are Trading Lower? Here Are Other Stocks Moving In Monday's Mid-Day Session
Why Bank of Marin Bancorp Shares Are Trading Lower? Here Are Other Stocks Moving In Monday's Mid-Day Session
Read Why Is Roth Capital Bullish On This Cancer-Focused Stock
Read Why Is Roth Capital Bullish On This Cancer-Focused Stock
Roth Capital notes that the FDA cleared Moleculin Biotech Inc's (NASDAQ: MBRX) WP1122 to start a Phase 1 trial in glioblastoma multiforme, which will be in addition to the drug's impending parallel clinical development in COVID-19. 
Why This Seelos Therapeutics Analyst Is Turning Bullish On Potential Trial Results
Why This Seelos Therapeutics Analyst Is Turning Bullish On Potential Trial Results
Part A results from the trial of Seelos Therapeutics Inc’s (NASDAQ: SEEL) intranasal ketamine product candidate, SLS-002, and the clarity around the timing of the Part B data release call for a change in recommendation, according to Roth Capital.
Why Seelos Therapeutics Stock Is Trading Higher Today
Why Seelos Therapeutics Stock Is Trading Higher Today
Seelos Therapeutics Inc (NASDAQ:SEEl) is trading higher Monday after Roth Capital analyst Jonathan Aschoff upgraded the stock from Neutral to Buy and raised the price target from $2.50 to $8.
Inovio To Report Q1 Results As It Develops Coronavirus Vaccine: What To Expect
Inovio To Report Q1 Results As It Develops Coronavirus Vaccine: What To Expect
Inovio Pharmaceuticals Inc (NASDAQ: INO) along with Moderna Inc (NASDAQ: MRNA) are 
Roth Downgrades Inovio On Vaulation Despite Positive MERS Vaccine Data
Roth Downgrades Inovio On Vaulation Despite Positive MERS Vaccine Data
Although Inovio Pharmaceuticals Inc (NASDAQ: INO) reported positive interim results from Phase 1 and 2a of its MERS vaccine, the valuation of the stock already reflects this, especially given the increase in share count since the end of 2019, according to Roth Capital Partners.
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.
Get Started for Free
Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2025 Benzinga | All Rights Reserved